March 19, 2018 / 5:19 PM / 6 months ago

BRIEF-OSE Immunotherapeutics Presents Positive OSE-172 Human Ex-Vivo And Preclinical Study Results

March 19 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:

* TO PRESENT NEW DATA ON OSE-172 AT AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

* ‍OSE-172, SIRPA ANTAGONIST, PREVENTS METASTASIS SPREAD IN AGGRESSIVE CANCER MODELS​

* OSE-172 ‍DECREASES TUMOR GROWTH AND SUPPRESSIVE FUNCTION OF TUMOR MYELOID CELLS

* ‍OSE-172 POTENTIATES DENDRITIC CELL TUMOR ANTIGEN CROSS-PRESENTATION INCREASING T-CELL SPECIFIC ACTIVATION​

* ‍DATA BEING PRESENTED ON OSE-172 INCLUDE RESULTS FROM HUMAN EX-VIVO AND PRECLINICAL STUDIES​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below